[Therapy of essential hypertension using a new beta-receptor blockader (timolol maleate) combined with hydrochlorothiazide].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D010919:Placebos; D011412:Propanolamines / Q000627:therapeutic use*; D013830:Thiadiazoles / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D009025:Morpholines; D010919:Placebos; D011412:Propanolamines; D013830:Thiadiazoles; D006852:Hydrochlorothiazide
Zur Therapie der essentiellen Hypertension mit einem neuen beta-Rezeptorenblocker (Timololmaleate) in Kombination mit Hydrochlorothiazid